Company Profile

Gene Biotherapeutics Inc. is a clinical-stage biotechnology company, which is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The technology platform is designed to biologically activate the human body's innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate is under clinical development, which is cleared by the United States Food and Drug Administration (FDA) for a Phase III clinical study.

Employees

Sector

Biotechnology & Medical Research

More about the company

30/03/22	Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
03/09/21	Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI

30/03/22	Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
03/09/21	Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
29/07/21	Gene Biotherapeutics, Inc. Announces Resignation of Murray H. Hutchison from the Board	CI
26/04/21	Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product	CI
28/05/20	Gene Biotherapeutics, Inc. Announces Management Changes	CI
28/05/20	Gene Biotherapeutics, Inc. Appoints James L. Grainer as Chief Financial Officer	CI
22/05/20	Gene Biotherapeutics, Inc. announced that it has received $1.7 million in funding from Nostrum Pharmaceuticals LLC	CI
20/03/19	Gene Biotherapeutics Inc. Announces Retirement of Gerald J. Lewis from its Board of Directors	CI
14/09/18	Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc	CI
08/01/18	Gene Biotherapeutics Mulls Acquisitions	CI
13/06/17	Taxus Cardium Pharmaceuticals Group Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Application	CI
01/03/17	Taxus Cardium Mulls Acquisitions	CI
14/12/16	Taxus Cardium Pharmaceuticals Group, Inc. Announces Board Retirements	CI

14/04/22	GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	AQ
31/03/22	GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
27/10/21	GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
03/09/21	GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
09/08/21	GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)	AQ

Manager	Title	Age	Since
Christopher Reinhard CEO	Chief Executive Officer	72	22/12/2003
James Grainer DFI	Director of Finance/CFO	71	22/05/2020
Ronald Shebuski CTO	Chief Tech/Sci/R&D Officer	73	22/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-1.06%	-1.63%	+1.26%	+18.27%	50.47B
REVOLUTION MEDICINES, INC.	-2.35%	-4.21%	+412.70%	+496.61%	44.56B
IQVIA HOLDINGS INC.	-1.54%	-1.05%	+40.14%	+15.66%	43.08B
BEONE MEDICINES AG	-2.50%	-4.08%	+7.46%	+71.91%	41.7B
CELLTRION, INC.	-0.94%	-1.77%	+18.34%	+46.84%	33.21B
MEDPACE HOLDINGS, INC.	-1.94%	-4.69%	+24.85%	+118.66%	16.77B
ASCENDIS PHARMA A/S	+5.23%	+4.31%	-	-	16.28B
EUROFINS SCIENTIFIC SE	-0.55%	-1.77%	+10.74%	+26.60%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.48%	-3.59%	+78.52%	+39.19%	13.92B
Average	-0.78%	-1.24%	+74.25%	+104.22%	30.51B
Weighted average by Cap.	-1.23%	-1.05%	+88.15%	+120.80%

Cardium Therapeutics Inc Stock NYSE

Stocks

CXM

US1419163043

Biotechnology & Medical Research

Latest news : Cardium Therapeutics Inc

Press Releases : Cardium Therapeutics Inc

Managers and Directors : Cardium Therapeutics Inc

Other Biotechnology & Medical Research

Company Profile

End-of-day quote NYSE
- ^USD	-